Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain

Women's Health

Volumn 11, Issue 1, 2015, Pages 19-28

  Ezzati, Mohammad ^a   Carr, Bruce R ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Bone mineral density; elagolix; endometriosis; GnRH antagonists; medical treatment

Indexed keywords

ANALGESIC AGENT; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; ASP 1707; CETRORELIX; DANAZOL; DEGARELIX; DIENOGEST; ELAGOLIX; GESTAGEN; GESTRINONE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KLH 2109; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE RECEPTOR MODULATOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAK 385; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL DERIVATIVE; FLUORINATED HYDROCARBON; GONADORELIN; PYRIMIDINE DERIVATIVE;

ACNE; ADD ON THERAPY; BREAST TENDERNESS; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ENDOMETRIOSIS RELATED PAIN; HEADACHE; HIRSUTISM; HORMONAL CONTRACEPTION; HOT FLUSH; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUATION; METRORRHAGIA; NAUSEA; PAIN; PELVIC PAIN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG SCREENING; FEMALE;

DRUG EVALUATION; ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROCARBONS, FLUORINATED; PAIN; PYRIMIDINES;

EID: 84920982682     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.68     Document Type: Review

References (75)

1. Giudice LC. Clinical practice. Endometriosis. N. Engl. J. Med. 362(25), 2389-2398 (2010).
2. Giudice LC, Kao LC. Endometriosis. Lancet 364(9447), 1789-1799 (2004).
3. Bulun SE. Endometriosis. N. Engl. J. Med. 360(3), 268-279 (2009).
4. Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat. Rev. Endocrinol. 10(5), 261-275 (2014).
5. Vercellini P, Fedele L, Aimi G, Pietropaolo G, Consonni D, Crosignani PG. Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum. Reprod. 22(1), 266-271 (2007).
6. Howard FM. Endometriosis and mechanisms of pelvic pain. J. Min. Invas. Gynecol. 16(5), 540-550 (2009).
7. Anaf V, Simon P, El Nakadi I et al. Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum. Reprod. 17(7), 1895-1900 (2002).
8. Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis and pelvic pain: relation to disease stage and localization. Fertil. Steril. 65(2), 299-304 (1996).
9. Nnoaham KE, Hummelshoj L, Webster P et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil. Steril. 96(2), 366-373 e368 (2011).
10. Simoens S, Hummelshoj L, D'Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum. Reprod. Update 13(4), 395-404 (2007).
11. Practice Committee of the American Society for Reproductive M. Endometriosis and infertility: a committee opinion. Fertil. Steril. 98(3), 591-598 (2012).
12. Practice Committee of the American Society for Reproductive M. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil. Steril. 101(4), 927-935 (2014).
13. Jacobson TZ, Duffy JM, Barlow D, Koninckx PR, Garry R. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst. Rev. 4, CD001300 (2009).
14. Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet. Gynecol. 111(6), 1285-1292 (2008).
15. Vercellini P, Carmignani L, Rubino T, Barbara G, Abbiati A, Fedele L. Surgery for deep endometriosis: a pathogenesisoriented approach. Gynecol. Obstet. Invest. 68(2), 88-103 (2009).
16. Vercellini P, Crosignani PG, Abbiati A, Somigliana E, Vigano P, Fedele L. The effect of surgery for symptomatic endometriosis: the other side of the story. Hum. Reprod. Update 15(2), 177-188 (2009).
17. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil. Steril. 90(5), 1583-1588 (2008).
18. Dunselman GA, Vermeulen N, Becker C et al. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 29(3), 400-412 (2014).
19. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil. Steril. 80(3), 560-563 (2003).
20. Vercellini P, Crosignani P, Somigliana E, Vigano P, Frattaruolo MP, Fedele L. 'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis. Hum. Reprod. 26(1), 3-13 (2011).
21. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum. Reprod. Update 18(6), 682-702 (2012).
22. Osteen KG, Bruner-Tran KL, Keller NR, Eisenberg E. Progesterone-mediated endometrial maturation limits matrix metalloproteinase (MMP) expression in an inflammatory-like environment: a regulatory system altered in endometriosis. Ann. NY Acad. Sci. 955, 37-47; discussion 86-38, 396-406 (2002).
23. Allen TK, Feng L, Grotegut CA, Murtha AP. Progesterone receptor membrane component 1 as the mediator of the inhibitory effect of progestins on cytokine-induced matrix metalloproteinase 9 activity in vitro. Reprod. Sci. 21(2), 260-268 (2014).
24. Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil. Steril. 84(5), 1375-1387 (2005).
25. Miyashita M, Koga K, Takamura M et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol. 30(9) 644-648 (2014).
26. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum. Reprod. 25(3), 633-641 (2010).
27. Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Women's Health 6(1), 27-35 (2010).
28. Telimaa S, Puolakka J, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and highdose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol. Endocrinol. 1(1), 13-23 (1987).
29. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst. Rev. 4, CD000068 (2001).
30. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst. Rev. 12, CD008475 (2010).
31. Brown J, Farquhar C. Endometriosis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. 3, CD009590 (2014).
32. Mclaren JS, Morris E, Rymer J. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update. Menopause Int. 18(2), 68-72 (2012).
33. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet. Gynecol. 91(1), 16-24 (1998).
34. Chwalisz K, Surrey E, Stanczyk FZ. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod. Sci. 19(6), 563-571 (2012).
35. Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J. Clin. Endocrinol. Metab. 92(6), 2205-2207 (2007).
36. Lindsay PC, Shaw RW, Bennink HJ, Kicovic P. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil. Steril. 65(2), 342-348 (1996).
37. Edmonds DK. Add-back therapy in the treatment of endometriosis: the European experience. Br. J. Obstet. Gynecol. 103(Suppl. 14), 10-13 (1996).
38. Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil. Steril. 67(1), 40-45 (1997).
39. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod. Biomed. Online 5(1), 12-16 (2002).
40. Hudelist G, Czerwenka K, Keckstein J et al. Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis. Reprod. Sci. 14(8), 798-805 (2007).
41. Zeitoun K, Takayama K, Sasano H et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J. Clin. Endocrinol. Metab. 83(12), 4474-4480 (1998).
42. Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil. Steril. 98(6), 1370-1379 (2012).
43. Nawathe A, Patwardhan S, Yates D, Harrison GR, Khan KS. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 115(7), 818-822 (2008).
44. Naqvi H, Sakr S, Presti T, Krikun G, Komm B, Taylor HS. Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. Biol. Reprod. 90(6), 121 (2014).
45. Chabbert-Buffet N, Pintiaux A, Bouchard P. The immninent dawn of SPRMs in obstetrics and gynecology. Mol. Cell. Endocrinol. 358(2), 232-243 (2012).
46. Taylor HS, Osteen KG, Bruner-Tran KL et al. Novel therapies targeting endometriosis. Reprod. Sci. 18(9), 814-823 (2011).
47. Stratton P, Sinaii N, Segars J et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet. Gynecol. 111(1), 88-96 (2008).
48. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol. 166(2), 740-745 (1992).
49. Jones RC. The effect of a luteinizing hormone-releasing hormone antagonist on experimental endometriosis in the rat. Acta Endocrinol. 114(3), 379-382 (1987).
50. Sharpe KL, Bertero MC, Vernon MW. Rapid regression of endometriosis by a new gonadotropin-releasing hormone antagonist in rats with surgically induced disease. Prog. Clin. Biol. Res. 323, 449-458 (1990).
51. Altintas D, Kokcu A, Tosun M, Cetinkaya MB, Kandemir B. Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis. J. Obstet. Gynaecol. Res. 34(6), 1014-1019 (2008).
52. Tan O, Bukulmez O. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Curr. Opin. Obstet. Gynecol. 23(4), 238-244 (2011).
53. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormonereceptor antagonists. Lancet 358(9295), 1793-1803 (2001).
54. Guo SW. An overview of the current status of clinical trials on endometriosis: issues and concerns. Fertil. Steril. 101(1), 183-190 (2014).
55. Cho N, Harada M, Imaeda T et al. Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J. Med. Chem. 41(22), 4190-4195 (1998).
56. Armer RE, Smelt KH. Non-peptidic GnRH receptor antagonists. Curr. Med. Chem. 11(22), 3017-3028 (2004).
57. Chen C, Wu D, Guo Z et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J. Med. Chem. 51(23), 7478-7485 (2008).
58. Tucci FC, Zhu YF, Struthers RS et al. 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. J. Med. Chem. 48(4), 1169-1178 (2005).
59. Randolph JT, Waid P, Nichols C et al. Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A. design, synthesis, and biological activity of cladinose replacement analogues. J. Med. Chem. 47(5), 1085-1097 (2004).
60. Anderes KL, Luthin DR, Castillo R et al. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J. Pharmacol. Exp. Ther. 305(2), 688-695 (2003).
61. Li H, Anderes KL, Kraynov EA et al. Discovery of a novel, orally active, small molecule gonadotropinreleasing hormone (GnRH) receptor antagonist. J. Med. Chem. 49(11), 3362-3367 (2006).
62. Hara T, Araki H, Kusaka M et al. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. J. Clin. Endocrinol. Metab. 88(4), 1697-1704 (2003).
63. Miwa K, Hitaka T, Imada T et al. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino) methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J. Med. Chem. 54(14), 4998-5012 (2011).
64. Pelletier JC, Chengalvala MV, Cottom JE et al. Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl] piperazin-1-yl}methyl)quinoxal ine (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R). J. Med. Chem. 52(7), 2148-2152 (2009).
65. Struthers RS, Chen T, Campbell B et al. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). J. Clin. Endocrinol. Metab. 91(10), 3903-3907 (2006).
66. Diamond MP, Carr B, Dmowski WP et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod. Sci. 21(3), 363-371 (2014).
67. Carr B, Chwalisz K, Jimenez R, Burke J, Jiang P, O'Brien C. A novel oral GnRH antagonist, elagolix, is effective for reducing endometriosis-associated pelvic pain: results of a 24-week randomized study. Fertil. Steril. 96(3), S45 (2011).
68. Imani R, Thai-Cuarto D, Jimenez R, Burke J, Kroll R, O'Brien C. Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis. Fertil. Steril. 92(3), S111-S112 (2009).
69. Struthers RS, Nicholls AJ, Grundy J et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropinreleasing hormone antagonist elagolix. J. Clin. Endocrinol. Metab. 94(2), 545-551 (2009).
70. Boyce M, Clark E, Johnston A, George M, Davies J, Hibberd M. Effects of single and repeated oral doses of TAK-013, a new non-peptide gonadotropin-releasing hormone (GnRH) antagonist, in healthy post-menopausal women. Fertil. Steril. 78, S281-S282 (2002).
71. Mcneilly AS, Crawford JL, Taragnat C, Nicol L, Mcneilly JR. The differential secretion of FSH and LH. regulation through genes, feedback and packaging. Reprod. Suppl. 61, 463-476 (2003).
72. Carr B, Giudice LC, Dmowski WP et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J. Endometr. Pelvic Pain Disord. 5(3), 105-115 (2013).
73. Carr BR, Dmowski WP, O'Brien C et al. Elagolix, an oral GnRH antagonist versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod. Sci. (2014) (In Press).
74. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am. J. Obstet. Gynecol. 139(6), 645-654 (1981).
75. Farrar JT, Young JP Jr, Lamoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2), 149-158 (2001).